CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) remains a significant challenge in cancer treatment.
• Identifying novel, specific therapeutic targets is crucial for improving PDAC outcomes.
• CEACAM7, a protein restricted to the colon and pancreas, emerged as a candidate target.

Purpose of the Study:

• To evaluate CEACAM7 as a novel therapeutic target for PDAC.
• To engineer chimeric antigen receptor (CAR) T cells targeting CEACAM7.
• To assess the efficacy of CEACAM7-specific CAR T cells in PDAC models.

Main Methods:

• Expression analysis of CEACAM7 in PDAC tumor sections and patient-derived cell cultures.
• Generation of CAR T cells engineered to target CEACAM7.
• In vitro and in vivo evaluation of CEACAM7 CAR T-cell antitumor activity using patient-derived xenograft models.

Main Results:

• CEACAM7 expression was confirmed in a substantial proportion of PDAC tumors, with minimal expression in normal tissues.
• High CEACAM7 expression was observed in patient-derived PDAC cultures, particularly in cancer stem cell populations.
• CEACAM7 CAR T cells effectively targeted antigen-positive tumor cells and induced remission in vivo.

Conclusions:

• CEACAM7 is identified as a viable therapeutic target for PDAC.
• CEACAM7-targeted CAR T-cell therapy demonstrates significant preclinical efficacy against PDAC.
• This approach holds promise for the development of novel immunotherapies for PDAC.